Vanda Gains FDA Nod for BYSANTI, Shares Spike as Company Secures Second Approval in Weeks
Vanda Pharmaceuticals announced FDA approval of BYSANTI (milsaperidone) for treatment of Bipolar I manic episodes and schizophrenia symptoms in adults, marking the company's second approval in under two months and triggering a 44% after-hours jump in its stock. The drug is classified as a New Chemical Entity with patent protection through 2044 and …